IO Biotech

Oncology

Interview at ESMO 2025 with Inge Marie Svane

ESMO25: Immuno-therapies and translational research in oncol...

Dr Inge Marie Svane – Professor in Clinical cancer immune therapy and director of the translational research centre, CCIT, on IO Biotech's ESMO25 data

News

IO Bio plans cancer vaccine filing despite trial miss

IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for approval regardless.

News

IO Biotech raises $155m to develop breakthrough cancer vacci...

IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) to further develop its cancer vaccine technology that has boosted eff

ESMO25: Immuno-therapies and translational research in oncol...

IO Bio plans cancer vaccine filing despite trial miss

IO Biotech raises $155m to develop breakthrough cancer vacci...

Patients not just at the table, but creating their own: In c...

Securing your ROI: Turning post-acquisition integration into...

Editor's Picks